Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQA3605 in treatment-naïve HBeAg-positive chronic hepatitis B (Phase II, randomized, double-blind, placebo-controlled)
CTR20251402Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing TQA3605 tablet arm with Placebo tablet arm (2 arms). Primary endpoint: Proportion of subjects with HBV DNA below lower limit of quantification. Started Apr 2025; status: terminated.
02
Drugs
TQA3605
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20251402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251402.